Table 2.
Univariate and Multivariate analysis of clinicopathological factors and immune and immune checkpoint biomarkers in EAC in the discovery and validation cohorts
| Variables | Discovery | Validation | ||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Univariate Analysis | ||||
| Mandard | 1.36 (1.032–1.792) | 0.029 | 1.833 (1.223–2.898) | 0.004 |
| T Stage | 0.879 (0.7058–1.095) | 0.25 | 1.764 (1.286–2.418) | < 0.001 |
| N Stage | 1.125 (0.7588–1.667) | 0.558 | 1.473 (1.156–1.878) | 0.002 |
| Node Pos | 1.03 (1.022–1.039) | < 0.001 | 2.180 (1.374–3.460) | 0.001 |
| CRM Involved | 3.533 (2.238–5.576) | < 0.001 | 1.258 (1.093–1.447) | 0.001 |
| CD3 | 0.4521 (0.2929–0.6977) | < 0.001 | – | – |
| CD4 | 0.6087 (0.3897–0.9509) | 0.029 | – | – |
| CD8 | 0.4932 (0.3188–0.7629) | 0.001 | – | – |
| CD45RO | 0.4271 (0.2587–0.7052) | < 0.001 | 0.835 (0.546–1.278) | 0.407 |
| ICOS | 0.5346 (0.3447–0.8291) | 0.005 | 0.656 (0.424–1.015) | 0.059 |
| PD-1 | 0.540 (0.337–0.866) | 0.010 | – | – |
| IDO-1 | 0.95 (0.7935–1.137) | 0.577 | – | – |
| PD-L1 | 0.762 (0.570–10.19) | 0.067 | – | – |
| CD45RO/ICOS | 0.394 (0.210–0.740) | 0.003 | 0.601 (0.363–0.996) | 0.048 |
| Multivariate Analysis | ||||
| Mandard | 1.321 (0.938–1.862) | 0.111 | 2.078 (1.161–3.718) | 0.014 |
| T Stage | 0.6846 (0.4968–0.943) | 0.020 | 0.926 (0.397–2.160) | 0.859 |
| N Stage | 1.264 (0.722–2.211) | 0.412 | 1.759 (0.709–4.365) | 0.223 |
| Node Pos | 1.0183 (1.006–1.0300) | 0.002 | 0.482 (0.117–1.984) | 0.312 |
| CRM Involved | 2.214 (1.2663–3.8711) | 0.002 | 1.171 (0.842–1.628) | 0.349 |
| CD45RO/ICOS | 0.445 (0.223–0.886) | 0.021 | 0.810 (0.336–1.953) | 0.639 |